• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Arcadia Biosciences (RKDA) Announces Strong Third Quarter 2024 Financial Results and Business Highlights

    11/12/24 4:05:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples
    Get the next $RKDA alert in real time by email

    – Total revenues increased 18% compared to Q3 2023 –

    – Zola® coconut water revenues grew 55% year over year –

    – Zola retail distribution expanded 68% vs. Q3 2023 –

    Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the third quarter and first nine months of 2024.

    "We are extremely pleased with our third-quarter 2024 results, which represent the progress we have made in transforming Arcadia's business as well as our ability to execute on the plan we laid out," said T.J. Schaefer, Arcadia's president and CEO. "Our total revenues increased 18 percent year over year, and we have significantly reduced our use of operating cash to the lowest levels in Arcadia's history as a public company.

    "Zola® coconut water revenues grew 55 percent in Q3, and new retail distribution increased 68 percent compared to last year. Additionally, Zola is gaining market share and growing faster than the coconut water category across all measured time periods," Schaefer said.

    Arcadia Biosciences, Inc.

    Financial Snapshot

    (Unaudited)

    ($ in thousands)

     

    Three Months Ended

    September 30,

    Nine Months Ended

    September 30,

    2024

     

    2023

     

    Favorable /

    (Unfavorable)

    2024

     

    2023

     

    Favorable /

    (Unfavorable)

    $

    %

    $

    %

    Total revenues

    1,537

     

    1,298

     

    239

     

    18

    %

    3,829

     

    3,677

     

    152

    4

    %

    Total operating expenses

    3,297

     

    2,695

     

    (602

    )

    (22

    %)

    5,198

     

    8,586

     

    3,388

    39

    %

    Loss from continuing operations

    (1,760

    )

    (1,397

    )

    (363

    )

    (26

    %)

    (1,369

    )

    (4,909

    )

    3,540

    72

    %

    Net loss attributable to common stockholders

    (1,612

    )

    (2,567

    )

    955

     

    37

    %

    (2,974

    )

    (11,128

    )

    8,154

    73

    %

    Certain previously reported financial information has been reclassified to conform to the current year presentation. Reclassifications are related to the presentation of the financial results of our former GoodWheatTM and body care brands as discontinued operations. The financial information above and narrative that follows relate to continuing operations unless stated otherwise.

    More detailed financial statements are included in the Form 8-K filed today, available in the Investors section of the company's website under SEC Filings.

    Revenues

    Revenue increased $239,000 and $152,000 during the third quarter and first nine months of 2024, respectively, compared to the same periods in 2023 driven by an increase in Zola sales.

    Operating Expenses

    Operating expenses increased by $602,000 during the third quarter of 2024 compared to the same period in 2023 primarily driven by higher revenues and employee severance costs. Operating expenses decreased by $3.4 million during the first nine months of 2024 compared to the same period in 2023 driven by a gain of $4.0 million related to the asset sale to Corteva in 2024.

    Cost of revenues increased $214,000 and $140,000 during the third quarter and first nine months of 2024 compared to the same periods in 2023, respectively, driven by higher revenues and input costs.

    Selling, general and administrative expenses increased $379,000 during the third quarter of 2024 compared to the same period in 2023 primarily due to employee severance expenses related to the change in management. Selling, general and administrative expenses increased $451,000 during the first nine months of 2024 compared to the same period in 2023 due to employee severance expenses as well as higher consulting and legal expenses.

    Net Loss Attributable to Common Stockholders

    Net loss attributable to common stockholders for the third quarter of 2024 was $1.6 million, or $1.18 per share, compared to $2.6 million, or $1.89 per share, for the same period in 2023. The improvement in net loss attributable to common stockholders for the third quarter of 2024 compared to the same period in 2023 was primarily driven by the year-over-year decrease in net loss from discontinued operations.

    Net loss attributable to common stockholders for the first nine months of 2024 was $3.0 million, or $2.18 per share, an $8.1 million improvement from the $11.1 million, or $9.31 per share, net loss for same period in 2023. The improvement in net loss attributable to common stockholders for the first nine months of 2024 compared to the same period in 2023 was primarily driven by the $4.0 million gain related to the asset sale to Corteva in 2024 as well as the year-over-year decrease in net loss from discontinued operations.

    Conference Call and Webcast

    The company has scheduled a conference call for 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss third-quarter results and key strategic achievements. Interested participants can join the conference call using the following options:

    • An audio-only webcast of the conference call will be available, with a link posted in the Investors section of Arcadia's website.
    • To join the live call, please register here, and a dial-in number and unique PIN will be provided.

    Following completion of the call, a recorded replay will be available in the Investors Section of the company's website.

    About Arcadia Biosciences, Inc.

    Since 2002, Arcadia Biosciences (NASDAQ:RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products that make every body feel good. For more information, visit www.arcadiabio.com.

    Safe Harbor Statement

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about the company and its products, including statements relating to the company's growth. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to, the risks set forth in filings that the company makes with the Securities and Exchange Commission from time to time, including in Arcadia's Annual Report on Form 10-K for the year ended December 31, 2023 and other filings. These forward-looking statements speak only as of the date hereof, and Arcadia Biosciences, Inc. disclaims any obligation to update these forward-looking statements.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241112069104/en/

    Get the next $RKDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RKDA

    DatePrice TargetRatingAnalyst
    1/3/2022$7.00 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RKDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Arcadia Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously

      1/3/22 6:06:17 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • HC Wainwright & Co. reiterated coverage on Arcadia Biosciences with a new price target

      HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $7.00 from $6.00 previously

      6/1/21 6:50:30 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Lake Street initiated coverage on Arcadia Biosciences with a new price target

      Lake Street initiated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $4.50

      5/11/21 12:00:10 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    SEC Filings

    See more
    • Arcadia Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)

      5/16/25 5:21:37 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form 10-Q filed by Arcadia Biosciences Inc.

      10-Q - Arcadia Biosciences, Inc. (0001469443) (Filer)

      5/8/25 8:07:59 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form 425 filed by Arcadia Biosciences Inc.

      425 - Arcadia Biosciences, Inc. (0001469443) (Subject)

      5/8/25 8:06:33 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Arcadia Biosciences Inc. (Amendment)

      SC 13G/A - Arcadia Biosciences, Inc. (0001469443) (Subject)

      2/14/24 2:55:48 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form SC 13G filed by Arcadia Biosciences Inc.

      SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)

      1/3/24 12:26:00 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form SC 13G filed by Arcadia Biosciences Inc.

      SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)

      2/14/23 1:22:05 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    Financials

    Live finance-specific insights

    See more

    $RKDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights

      -- Revenues increase 22% year over year driven by 90% growth in Zola® ---- Arcadia sells patents for $750K and eliminates $1M in liabilities ---- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025. The company has scheduled a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. "The momentum we experienced in the second half of 2024 has

      5/8/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference Call

      DALLAS, April 29, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the first quarter of 2025 on May 8, 2025. The company has scheduled a conference call for 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. Interested participants can join the conference call using the following options: An audio-only webcast of the conference call will be available, with a link posted in the Investors section of Arcadia's website.To join the live call, please register

      4/29/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights

      -- Year-over-year revenues grew 56% in Q4 and 13% for full year -- -- Zola® year-over-year revenues increased 124% in Q4 and 46% for full year -- -- Company plans business combination with Roosevelt Resources, Inc. -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2024. "We are extremely pleased with the progress we made in 2024, particularly in the second half of the year following the sale of our GoodWheat™ assets," said T.J. Schaefer, president and CEO. "Our focus on Zola® coconut water led to 80 percent revenue growth f

      3/20/25 4:05:00 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Leadership Transition

      -- CEO Stan Jacot replaced by CFO Thomas J. Schaefer -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced that CEO Stan Jacot has left the company and been replaced by Thomas J. Schaefer, effective July 5, 2024. Schaefer was previously Arcadia's chief financial officer and will be replaced in that role by Mark Kawakami, Arcadia's current vice president of finance. "On behalf of Arcadia, I would like to thank Stan for his many contributions to the company," said Board of Directors Chairman Kevin Comcowich. "Under his leadership, Arcadia expanded the GoodWheat brand into three categories, sold the brand to

      7/9/24 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Appoints Kevin Comcowich to Interim CEO

      DAVIS, Calif., Dec. 20, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief executive officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO. As previously announced on September 7, 2021, the board of directors launched a national search for a new CEO as the company further expands into the consumer packaged goods (CPG) sector.

      12/20/21 10:55:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Appoints Seasoned CPG Sales Executive Brian Schaffer to Senior Vice President of Sales

      DAVIS, Calif., Nov. 22, 2021 /PRNewswire/ --  Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has named Brian Schaffer as senior vice president of sales, as the company continues to expand its consumer goods platforms. A seasoned sales and general management executive with deep CPG experience, Schaffer has a proven track record of building and leading world class sales organizations. He is tasked with driving the retail launch of Arcadia's GoodWheat brand, a company priority in 2022 as it w

      11/22/21 8:00:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Kawakami Mark

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      5/12/25 8:56:01 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • SEC Form 4 filed by Chief Executive Officer Schaefer Thomas J.

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      5/12/25 8:48:31 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Chief Financial Officer Kawakami Mark bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 35% to 2,681 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      2/5/25 7:34:41 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Kawakami Mark bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 35% to 2,681 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      2/5/25 7:34:41 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Chief Executive Officer Schaefer Thomas J. bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 33% to 2,819 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      2/5/25 7:24:18 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Chief Financial Officer Kawakami Mark bought $1,442 worth of shares (700 units at $2.06), increasing direct ownership by 55% to 1,981 units (SEC Form 4)

      4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

      8/20/24 8:11:11 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples

    $RKDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights

      -- Revenues increase 22% year over year driven by 90% growth in Zola® ---- Arcadia sells patents for $750K and eliminates $1M in liabilities ---- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025. The company has scheduled a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. "The momentum we experienced in the second half of 2024 has

      5/8/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Date of First Quarter 2025 Financial Results and Business Highlights Conference Call

      DALLAS, April 29, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today announced that it will release its financial and business results for the first quarter of 2025 on May 8, 2025. The company has scheduled a conference call for 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. Interested participants can join the conference call using the following options: An audio-only webcast of the conference call will be available, with a link posted in the Investors section of Arcadia's website.To join the live call, please register

      4/29/25 8:02:00 AM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples
    • Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2024 Financial Results and Business Highlights

      -- Year-over-year revenues grew 56% in Q4 and 13% for full year -- -- Zola® year-over-year revenues increased 124% in Q4 and 46% for full year -- -- Company plans business combination with Roosevelt Resources, Inc. -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the fourth quarter and full year of 2024. "We are extremely pleased with the progress we made in 2024, particularly in the second half of the year following the sale of our GoodWheat™ assets," said T.J. Schaefer, president and CEO. "Our focus on Zola® coconut water led to 80 percent revenue growth f

      3/20/25 4:05:00 PM ET
      $RKDA
      Farming/Seeds/Milling
      Consumer Staples